A $0.03 Pill That Could Save Maternal Lives: An Update on the State of Low-Dose Aspirin for Preeclampsia Prevention- part 1
Preeclampsia is the second leading cause of maternal mortality worldwide, complicating roughly 4% of all pregnancies in the United States, and accounting for 6% of all preterm births. It can cause seizures, stroke, liver failure, and even death. For women at high risk, a small, over-the-counter pill can offer evidence-based protection.
Low-dose aspirin (LDA) is the only currently known preventative therapy for pre-eclampsia. Yet, so many high-risk pregnant women who could benefit from LDA are still not taking it despite the medical evidence in support of its benefits.
What does the latest U.S. evidence show?
The U.S. Preventive Services Task Force (USPSTF) issued a “Grade B recommendation” in 2021, reaffirming its 2014 guidance that daily low-dose aspirin (81 mg/day) should be initiated after 12 weeks of gestation in those at high risk for preeclampsia. Under the Affordable Care Act, a Grade B recommendation means insurers are required to cover LDA for eligible patients.
High-risk individuals are those with a prior history of preeclampsia, chronic hypertension,
pregestational diabetes, pregnancy with multiples, kidney disease, and autoimmune conditions. The USPSTF's evidence review confirmed substantial overall benefit with no statistically significant increase in risk of placental abruption, postpartum hemorrhage, or miscarriage.
By Brittany de Soto Palmer
Dejar un comentario
Los comentarios se aprobarán antes de mostrarse.
Ver artículo completo
The High Quality Maternova Non-pneumatic anti-shock garment (NASG)
High quality ISO 13485 and CE-marked Non-pneumatic anti shock garments (NASG) produced by Maternova for use by midwives and obstetricians all over the world to save lives threatened by postpartum hemorrhage. Our NASGS adhere to the highest standards and are trusted by hundreds of clinicians.
A $.03 pill that could prevent maternal deaths; Part 5
The USPSTF, ACOG, the Society for Maternal-Fetal Medicine, and FIGO all recommend low dose aspirin (LDA) for high-risk pregnancies. The barriers are systemic, behavioral, and structural.
A $.03 pill that could save maternal lives: low dose aspirin.... Part 3
A 2025 study at a Federally Qualified Health Center (FQHC) serving a socially vulnerable population proved that with implementation of a universal low dose aspirin protocol, adherence jumped from 8.7% to 75%.
